Chugai takes on two more Roche personalised medicine projects for Japan
This article was originally published in Scrip
Chugai has acquired rights to another two molecules from parent Roche's pipeline for development and marketing in Japan, signing licensing deals for MetMab for non-small cell lung (NSCLC) and potentially other cancers and lebrikizumab for bronchial asthma as part of the group's 'personalised medicine' strategy.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.